Swiss Re AG (SREN)
SIX Swiss Exchange · Switzerland · prices in CHF · close of 22 Oct 2026
Key indicators
| Last close | CHF 154.35 |
|---|---|
| 52-week range | 114.05 – 154.60 |
| Return, 1 month / 3 months | +11.4% / +17.4% |
| Return, 1 year / 3 years | +8.8% / +87.2% |
| Trend | Uptrend |
| RSI (14) | 78 |
| Volatility (1 year) | 21.2% |
| Worst drawdown (1 year) | -21.9% |
| Average daily value traded | 99.50M CHF |
| Dividend yield | 4.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Swiss Re AG is a reinsurance company based in Zurich, Switzerland. It takes on risks transferred from insurance companies and large corporate customers, covering areas such as property catastrophe, casualty, life and health. Through its reinsurance and commercial insurance operations, it also offers risk transfer solutions and related services to clients in markets around the world, helping them manage exposure to large or unusual losses.
Swiss Re AG trades under the code SREN on the SIX Swiss Exchange in Switzerland, with its price quoted in Swiss francs (CHF). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Swiss Re AG (SREN) trades on the SIX Swiss Exchange in Switzerland. It last closed at CHF 154.35 on 22 October 2026.
Its price-based Market X-Ray is 76 out of 100 (a strong price profile), ranking 10 of 225 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 8.8% and over the last three months it rose 17.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on SIX Swiss Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 88 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 19.1% | ||
| From 52-week high | 0.0% | ||
| Momentum | 64 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 17.4% | ||
| 6-month return | 18.1% | ||
| 12-month return, skipping the last month | -2.4% | ||
| Stability (higher is calmer) | 67 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 21.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -21.9% | ||
| Liquidity | 97 · Strong | Trades actively. | |
| Average daily value traded | 99.50M CHF | ||
| Zero-volume days | 0.0% | ||
| Income | 71 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 4.1% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Liquidity: Trades actively.
- Income: Dividend is high and has been paid regularly.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +3.1% |
|---|---|
| 1 month | +11.4% |
| 3 months | +17.4% |
| 6 months | +18.0% |
| 1 year | +8.8% |
| 3 years | +87.2% |
| 5 years | +152.3% |
Signals
| 50-day / 200-day average | 141.91 / 129.62 |
|---|---|
| Golden / death cross (60 days) | Golden, 57 days ago |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.40 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 Apr 2026 | CHF 6.3008 |
| 15 Apr 2025 | CHF 6.0075 |
| 16 Apr 2024 | CHF 6.2155 |
| 14 Apr 2023 | CHF 5.7206 |
| 19 Apr 2022 | CHF 5.9000 |
| 20 Apr 2021 | CHF 5.9000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on SIX Swiss Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.